share_log

3: Initial statement of beneficial ownership of securities-Director Fry Simon Jeremy

3: Initial statement of beneficial ownership of securities-Director Fry Simon Jeremy

3:首次持股聲明-董事 Fry Simon Jeremy
美股SEC公告 ·  2024/12/21 06:10

Moomoo AI 已提取核心訊息

Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
Simon Jeremy Fry has been appointed as a Director of Conduit Pharmaceuticals Inc, effective December 18, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating an initial statement of beneficial ownership of securities.The filing reveals that Fry directly owns 200,000 shares of Conduit Pharmaceuticals' common stock. This substantial shareholding suggests a significant commitment to the company and aligns the new director's interests with those of other shareholders.The Form 3 was signed by Fry on December 20, 2024, two days after the event requiring the statement. No derivative securities were reported in the filing, indicating that Fry's ownership is currently limited to common stock.
西蒙·傑里米·弗賴被任命爲Conduit Pharmaceuticals Inc的董事,任職自2024年12月18日。該信息在向美國證券交易委員會提交的Form 3文件中披露,表明了證券的初步權益聲明。文件顯示,弗賴直接持有Conduit Pharmaceuticals普通股200,000股。這一 substantial 參股金融 表明了對公司的重大承諾,並將新董事的利益與其他股東的利益對齊。Form 3於2024年12月20日由弗賴簽署,距要求聲明的事件發生已過去兩天。文件中未報告衍生證券,表明弗賴的所有權目前僅限於普通股。
西蒙·傑里米·弗賴被任命爲Conduit Pharmaceuticals Inc的董事,任職自2024年12月18日。該信息在向美國證券交易委員會提交的Form 3文件中披露,表明了證券的初步權益聲明。文件顯示,弗賴直接持有Conduit Pharmaceuticals普通股200,000股。這一 substantial 參股金融 表明了對公司的重大承諾,並將新董事的利益與其他股東的利益對齊。Form 3於2024年12月20日由弗賴簽署,距要求聲明的事件發生已過去兩天。文件中未報告衍生證券,表明弗賴的所有權目前僅限於普通股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息